CEFTRIAXONE Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Ceftriaxone, and when can generic versions of Ceftriaxone launch?
Ceftriaxone is a drug marketed by Acs Dobfar, Agila Speclts, Atlantide, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu, Samson Medcl, Sandoz, Sandoz Inc, Teva, Akorn, Astral, Cephazone Pharma, Hikma Farmaceutica, Teva Pharms Usa, B Braun, Baxter Hlthcare, and Hikma. and is included in thirty-six NDAs.
The generic ingredient in CEFTRIAXONE is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ceftriaxone
A generic version of CEFTRIAXONE was approved as ceftriaxone sodium by ASTRAL on January 20th, 2017.
Summary for CEFTRIAXONE
| US Patents: | 0 |
| Applicants: | 22 |
| NDAs: | 36 |
| Finished Product Suppliers / Packagers: | 17 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Clinical Trials: | 165 |
| Patent Applications: | 7,092 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CEFTRIAXONE |
| DailyMed Link: | CEFTRIAXONE at DailyMed |
Recent Clinical Trials for CEFTRIAXONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Beijing Tiantan Hospital | Phase 3 |
| Tianjin Medical University General Hospital | Phase 2 |
| University of Washington | N/A |
Pharmacology for CEFTRIAXONE
| Drug Class | Cephalosporin Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for CEFTRIAXONE
US Patents and Regulatory Information for CEFTRIAXONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065262-001 | Jun 29, 2006 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Bedford | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065465-002 | Aug 18, 2008 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Atlantide | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065391-001 | Apr 12, 2007 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Fresenius Kabi Usa | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065245-004 | Feb 15, 2006 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
